FDA approves first coagulation factor-albumin fusion protein to treat patients with hemophilia B - FDA Press Releases

The U.S. Food and Drug Administration today approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved, and the second Factor IX fusion protein product approved in the U.S. that is modified to last longer in the blood.

from FDA Press Releases RSS Feed https://ift.tt/3aiUsts
via IFTTT